TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20196703

Group type: EXPERIMENTAL
Intervention: Sequential exposure to color conditions (same, mixed, unique)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Set 1 and Set 2 exposures
Number of subjects: 60
Study: 18045306

Group type: EXPERIMENTAL
Intervention: IVIG (400 mg/kg once a month)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 15
Study: 16086839

Group type: EXPERIMENTAL
Intervention: Topical diclofenac solution (Pennsaid)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Vehicle control solution
Number of subjects: 216
Study: 11936244

Group type: EXPERIMENTAL
Intervention: Global Deterioration Scale (GDS) scores between 4 and 6 (n = 21)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Global Deterioration Scale (GDS)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Global Deterioration Scale (GDS) score classification
Number of subjects: 39
Study: 10547166

Group type: EXPERIMENTAL
Intervention: Remote, intercessory prayer (prayer group)
Number of subjects: 990

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 990
Study: 8705087

Group type: EXPERIMENTAL
Intervention: Oral hydrochlorothiazide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral furosemide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous furosemide
Number of subjects: 12

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 12
Study: 1719655

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 206

Group type: COMPARATOR
Intervention: Dextran 70
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 206
Study: 6667629

Group type: EXPERIMENTAL
Intervention: Aqueous beclomethasone dipropionate nasal spray (100 micrograms into each nostril twice daily for 14 days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional pressurized spray
Number of subjects: 42
Study: 30561237

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6) inhibitor (tocilizumab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interleukin-13 (IL-13)
Number of subjects: 0
Study: 29110681

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Add-on treatment with mianserin
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Add-on treatment with Imagery Rehearsal Therapy (IRT)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Combination of mianserin and IRT
Number of subjects: 230
Study: 25554997

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention on diet and physical activity for 18 months
Number of subjects: 129

Group type: COMPARATOR
Intervention: Non-depressed individuals
Number of subjects: 129
Study: 23494559

Group type: EXPERIMENTAL
Intervention: JobTIPS employment program (training intervention)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no training intervention)
Number of subjects: 22
Study: 22097195

Group type: EXPERIMENTAL
Intervention: CM comprehensive regimen (intravenous dripping of Chinese herbal preparation, oral administration of Chinese herbal decoction, and point application)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single-agent maintenance chemotherapy (pemetrexed, docetaxel, or gemcitabine)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CM comprehensive regimen (MT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single-agent maintenance chemotherapy (control)
Number of subjects: 50
Study: 19705345

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg bid
Number of subjects: 546

Group type: COMPARATOR
Intervention: Gliclazide up to 320 mg/day
Number of subjects: 546
Study: 16622596

Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alpha treatment (6 microg/kg once a week for 8 weeks, then 3 microg/kg/week)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Observation only (control group)
Number of subjects: 40
Study: 15087628

Group type: EXPERIMENTAL
Intervention: 25 mg ropivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 25 mg levobupivacaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: 100 mg lidocaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: 5 ml intravenous saline
Number of subjects: 120
Study: 11356389

Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 1524689

Group type: EXPERIMENTAL
Intervention: Rembrandt dentifrice
Number of subjects: 18

Group type: COMPARATOR
Intervention: Crest dentifrice
Number of subjects: 18
Study: 3904435

Group type: EXPERIMENTAL
Intervention: Isoxicam (133 mg per day Week 1, 166 mg per day Week 2, 200 mg per day Weeks 3 to 12)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Indomethacin (100 mg per day Week 1, 125 mg per day Week 2, 150 mg per day Weeks 3 to 12)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Isoxicam
Number of subjects: 365

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 365
Study: 30206088

Group type: EXPERIMENTAL
Intervention: apixaban 2.5 mg twice daily
Number of subjects: 222

Group type: COMPARATOR
Intervention: dose-adjusted vitamin K antagonist therapy (target international normalised ratio 2.0-3.0)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: apixaban
Number of subjects: 222

Group type: COMPARATOR
Intervention: dose-adjusted vitamin K antagonist therapy
Number of subjects: 222
Study: 26691895

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 175
Study: 24665869

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural self‐help (CBSH)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural self‐help augmented with implementation intentions (CBSH+)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 75
Study: 22852870

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg BID
Number of subjects: 2446

Group type: COMPARATOR
Intervention: Diclofenac SR 75 mg BID plus omeprazole 20 mg daily
Number of subjects: 2446
Study: 20306614

Group type: EXPERIMENTAL
Intervention: Skin Rehabilitation Nursing Program (SRNP) - massage therapy 30 minutes three times a week for 3 months
Number of subjects: 26

Group type: COMPARATOR
Intervention: Typical care (control group)
Number of subjects: 26
Study: 18256079

Group type: EXPERIMENTAL
Intervention: Sulene-polyethylene liner
Number of subjects: 90

Group type: COMPARATOR
Intervention: Durasul-polyethylene liner
Number of subjects: 90
Study: 16986125

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 0
Study: 12868789

Group type: EXPERIMENTAL
Intervention: Transfusion of unprocessed CPB volume
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transfusion of processed CPB volume
Number of subjects: 0
Study: 10894284

Group type: EXPERIMENTAL
Intervention: ZDV/3TC/IDV (indinavir) for 52 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: ZDV/3TC for 52 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZDV/3TC/NFV (nelfinavir) for 28 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: ZDV/3TC for 28 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZDV/3TC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZDV/3TC/IDV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZDV/3TC/PI
Number of subjects: 0
Study: 8783673

Group type: EXPERIMENTAL
Intervention: Amifostine plus cyclophosphamide/cisplatin (CP)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Cyclophosphamide/cisplatin (CP)
Number of subjects: 242
Study: 1815310

Group type: EXPERIMENTAL
Intervention: Valverde relaxation dragées
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bromazepam (3 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3549572

Group type: EXPERIMENTAL
Intervention: Biofiltration (BF) with AN69s
Number of subjects: 39
Study: 30106870

Group type: EXPERIMENTAL
Intervention: NIO Pediatric
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Arrow EZ-IO
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: BIG Pediatric
Number of subjects: 75

Group type: COMPARATOR
Intervention: Jamshidi needle (manual device)
Number of subjects: 75
Study: 30183779

Group type: EXPERIMENTAL
Intervention: Online depression intervention
Number of subjects: 445

Group type: COMPARATOR
Intervention: Attention control intervention
Number of subjects: 445
Study: 27297048

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Waiting-list condition (WL)
Number of subjects: 155
Study: 24968759

Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5% applied preoperatively
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1% applied preoperatively
Number of subjects: 94

Group type: COMPARATOR
Intervention: Ofloxacin 0.3% (control) applied in the other eye
Number of subjects: 94
Study: 22856341

Group type: EXPERIMENTAL
Intervention: Interval exercise (INT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Steady-state exercise (SS)
Number of subjects: 18
Study: 21344132

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 120

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 120
Study: 19092629

Group type: EXPERIMENTAL
Intervention: Dupaco positioner
Number of subjects: 66

Group type: COMPARATOR
Intervention: ROHO positioner
Number of subjects: 66

Group type: COMPARATOR
Intervention: OSI positioner
Number of subjects: 66
Study: 17158494

Group type: EXPERIMENTAL
Intervention: VADO-based intervention
Number of subjects: 85

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 85
Study: 14503054

Group type: EXPERIMENTAL
Intervention: WCA + CT
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: WCA
Number of subjects: 148

Group type: COMPARATOR
Intervention: CT
Number of subjects: 148
Study: 11101469

Group type: EXPERIMENTAL
Intervention: HCA supplementation (3.1 mL/kg body weight of an HCA solution at 19 g/L)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HCA supplementation
Number of subjects: 10
Study: 9019000

Group type: EXPERIMENTAL
Intervention: Operating microscope
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Binocular loupe
Number of subjects: 121

Group type: COMPARATOR
Intervention: Unaided eye
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Consultants with operating microscope
Number of subjects: 121

Group type: COMPARATOR
Intervention: Junior residents with operating microscope
Number of subjects: 121
Study: 1389932

Group type: EXPERIMENTAL
Intervention: New Ophthalmic Delivery System (NODS) containing pilocarpine nitrate
Number of subjects: 12

Group type: COMPARATOR
Intervention: 2% w/v pilocarpine nitrate solution
Number of subjects: 12
Study: 2857025

Group type: EXPERIMENTAL
Intervention: Buccal morphine (13.3 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intramuscular morphine (13.3 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Buccal morphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 40
Study: 31023358

Group type: EXPERIMENTAL
Intervention: LUS-based fluid management protocol with daily assessment of BLS and diuretics (Furosemide) when BLS ≥ 15.
Number of subjects: 500

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 500
Study: 28935219

Group type: EXPERIMENTAL
Intervention: Medical abortion pills dispensed by trained pharmacy workers in Makwanpur district (GROUP 2)
Number of subjects: 992

Group type: COMPARATOR
Intervention: Medical abortion pills dispensed by pharmacy workers in Chitwan district (GROUP 1)
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: Medical abortion pills dispensed by trained pharmacy workers in both groups
Number of subjects: 992
Study: 27615007

Group type: EXPERIMENTAL
Intervention: Test formulation of omeprazole (20 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reference formulation of omeprazole (20 mg)
Number of subjects: 30
Study: 25591469

Group type: EXPERIMENTAL
Intervention: Finerenone 1.25-20 mg once daily
Number of subjects: 821

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821
Study: 22650125

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Sanyinjiao (SP 6)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Sham-acupuncture
Number of subjects: 111

Group type: COMPARATOR
Intervention: Blank control
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 111
Study: 20944049

Group type: EXPERIMENTAL
Intervention: Postdated delayed prescriptions
Number of subjects: 149

Group type: COMPARATOR
Intervention: Usual delayed prescriptions
Number of subjects: 149
Study: 17974490

Group type: EXPERIMENTAL
Intervention: Nabilone (0.5 mg PO at bedtime to 1 mg BID over 4 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16208639

Group type: EXPERIMENTAL
Intervention: Pravastatin, ramipril, aspirin, and a combination B vitamin plus individualized cardiovascular prevention education
Number of subjects: 41

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 41
Study: 11978292

Group type: EXPERIMENTAL
Intervention: Methotrexate (50 mg/m²) followed by misoprostol (800 micrograms vaginally)
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Mifepristone (600 mg) followed by misoprostol (400 micrograms orally)
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Mifepristone
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1042
Study: 10425053

Group type: EXPERIMENTAL
Intervention: ThinPrep
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional smear
Number of subjects: 75
Study: 8526180

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with grass allergen extracts
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 2314573

Group type: EXPERIMENTAL
Intervention: LD children
Number of subjects: 32

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 32
Study: 7030442

Group type: EXPERIMENTAL
Intervention: Propranolol (640 mg/day)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 31420401

Group type: EXPERIMENTAL
Intervention: Robot-assisted radical cystectomy with intracorporeal urinary diversion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open radical cystectomy
Number of subjects: 0
Study: 26811130

Group type: EXPERIMENTAL
Intervention: Pea fiber (PF; 15 g/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 50
Study: 25885704

Group type: EXPERIMENTAL
Intervention: Waupaca Eating Smart (WES) intervention in restaurants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Waupaca Eating Smart (WES) intervention in food stores
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control community (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Waupaca Eating Smart (WES) intervention overall
Number of subjects: 0
Study: 23487258

Group type: EXPERIMENTAL
Intervention: Screen-positive women with EPDS score of 10 or higher
Number of subjects: 1396
Study: 21297005

Group type: EXPERIMENTAL
Intervention: Medial collagen meniscus implant (MCMI)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Partial medial meniscectomy (PMM)
Number of subjects: 33
Study: 19651919

Group type: EXPERIMENTAL
Intervention: Intensive diet-exercise counseling
Number of subjects: 522

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 522
Study: 16840742

Group type: EXPERIMENTAL
Intervention: Hyperoxia (40% O(2), 60% N(2))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Normoxic helium (21% O(2), 79% He)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Helium-hyperoxia (40% O(2), 60% He)
Number of subjects: 10
Study: 12756385

Group type: EXPERIMENTAL
Intervention: Plant stanol spread
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Plant sterol ester spread
Number of subjects: 23
Study: 10931512

Group type: EXPERIMENTAL
Intervention: Combination drug with multiple doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unbalanced factorial design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjusted p-value approach
Number of subjects: 0
Study: 9343838

Group type: EXPERIMENTAL
Intervention: High-vegetable, reduced-fat, and increased-fiber diet intervention with intensive telephone counseling
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 93
Study: 8345542

Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg kg‐1)
Number of subjects: 771

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 771
Study: 3667023

Group type: COMPARATOR
Intervention: Normoxic conditions (sea level)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hypoxic conditions (3000 m altitude)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both conditions (Normoxia and Hypoxia)
Number of subjects: 6
Study: 31924632

Group type: EXPERIMENTAL
Intervention: parecoxib/celecoxib
Number of subjects: 246

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 246
Study: 29913033

Group type: COMPARATOR
Intervention: Volatile-based anaesthesia and postoperative sedation
Number of subjects: 157

Group type: COMPARATOR
Intervention: Propofol-based anaesthesia and postoperative sedation
Number of subjects: 157
Study: 27353367

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: EMDR
Number of subjects: 70
Study: 24423370

Group type: EXPERIMENTAL
Intervention: Educational outreach visits (one for each guideline) at the workplace during a six-month period
Number of subjects: 220

Group type: COMPARATOR
Intervention: Single unrelated group training session
Number of subjects: 220
Study: 22565413

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral program for coping with cancer (4 weeks)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 186
Study: 21434398

Group type: EXPERIMENTAL
Intervention: Short-term non-thermal radiofrequency electromagnetic field (RF EMF) exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of RF EMF exposure and monotonous activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conditions of theta- or beta2-range domination in EEG background
Number of subjects: 0
Study: 19062483

Group type: EXPERIMENTAL
Intervention: Epidural balloon (EB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Air (LORA)
Number of subjects: 50
Study: 15529811

Group type: EXPERIMENTAL
Intervention: Human milk (HM) fortified with Enfamil Human Milk fortifier
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Human milk (HM) fortified with Eoprotin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Similac 24 preterm formula
Number of subjects: 30
Study: 11171650

Group type: EXPERIMENTAL
Intervention: Preferential reduction of IGF‐I feedback signal strength
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preferential enhancement of IGF‐I feedback signal strength
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective attenuation of GH‐releasing hormone feedforward signal intensity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective augmentation of GH‐releasing hormone feedforward signal intensity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective attenuation of gonadotropin‐releasing hormone feedforward signal intensity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective augmentation of gonadotropin‐releasing hormone feedforward signal intensity
Number of subjects: 0
Study: 9628521

Group type: EXPERIMENTAL
Intervention: 3.75 mg leuprorelin acetate depot per month i.m. + 20 mg ethinyloestradiol + 0.15 mg desogestrel orally for 3 weeks (group A)
Number of subjects: 27

Group type: COMPARATOR
Intervention: 3.75 mg leuprorelin acetate depot per month i.m. + placebo (group P)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups (A and P)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combined oestrogen/progestin add‐back therapy (group A)
Number of subjects: 27
Study: 7511753

Group type: EXPERIMENTAL
Intervention: Captopril combined with acetylsalicylic acid (ASA) 236 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Captopril alone
Number of subjects: 13
Study: 3337793

Group type: EXPERIMENTAL
Intervention: General anesthesia with spontaneous ventilation (nitrous oxide and halothane in oxygen)
Number of subjects: 152

Group type: COMPARATOR
Intervention: General anesthesia with controlled ventilation (fentanyl, nitrous oxide and halothane in oxygen)
Number of subjects: 152
Study: 28332259

Group type: EXPERIMENTAL
Intervention: Specific pregnancy related messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: General health messages
Number of subjects: 0
Study: 28571589

Group type: EXPERIMENTAL
Intervention: Clinician education and prospective audit and feedback interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of general medicine inpatients
Number of subjects: 0
Study: 26597295

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (5 sessions, 90 min each)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Behavioral activation intervention (5 sessions, 90 min each)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 180
Study: 23810044

Group type: EXPERIMENTAL
Intervention: Self-etching primer
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional acid etching
Number of subjects: 34
Study: 21190109

Group type: EXPERIMENTAL
Intervention: 3 months of VR training
Number of subjects: 50

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 50
Study: 18422741

Group type: EXPERIMENTAL
Intervention: Alcohol consumption <25 g/week
Number of subjects: 1616

Group type: EXPERIMENTAL
Intervention: Alcohol consumption 25-175 g/week
Number of subjects: 1616

Group type: EXPERIMENTAL
Intervention: Alcohol consumption >175 g/week
Number of subjects: 1616

Group type: EXPERIMENTAL
Intervention: Women without flushing after drinking
Number of subjects: 1616
Study: 16948934

Group type: EXPERIMENTAL
Intervention: Stiripentol (n = 17)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 67